Kussie P - Search Results

1

Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature.

May C, Doody JF, Abdullah R, Balderes P, Xu X, Chen CP, Zhu Z, Shapiro L, Kussie P, Hicklin DJ, Liao F, Bohlen P. May C, et al. Among authors: kussie p. Blood. 2005 Jun 1;105(11):4337-44. doi: 10.1182/blood-2005-01-0010. Epub 2005 Feb 8. Blood. 2005. PMID: 15701713 Free article.

2

Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.

Liao F, Doody JF, Overholser J, Finnerty B, Bassi R, Wu Y, Dejana E, Kussie P, Bohlen P, Hicklin DJ. Liao F, et al. Among authors: kussie p. Cancer Res. 2002 May 1;62(9):2567-75. Cancer Res. 2002. PMID: 11980651

3

Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.

Li Y, Li H, Wang MN, Lu D, Bassi R, Wu Y, Zhang H, Balderes P, Ludwig DL, Pytowski B, Kussie P, Piloto O, Small D, Bohlen P, Witte L, Zhu Z, Hicklin DJ. Li Y, et al. Among authors: kussie p. Blood. 2004 Aug 15;104(4):1137-44. doi: 10.1182/blood-2003-07-2585. Epub 2004 Apr 22. Blood. 2004. PMID: 15105287 Free article.

4

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL. Burtrum D, et al. Among authors: kussie p. Cancer Res. 2003 Dec 15;63(24):8912-21. Cancer Res. 2003. PMID: 14695208

5

Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed.

Ludwig DL, Witte L, Hicklin DJ, Prewett M, Bassi R, Burtrum D, Pereira DS, Jimenez X, Fox F, Saxena B, Zhou Q, Ma Y, Kang X, Patel D, Barry M, Kussie P, Zhu Z, Russell DA, Petersen WL, Jury TP, Gaitan-Gaitan F, Moran DL, Delannay X, Storrs BS, Tou J, Zupec ME, Gustafson KS, McIntyre J, Tarnowski SJ, Bohlen P. Ludwig DL, et al. Among authors: kussie p. Hum Antibodies. 2004;13(3):81-90. Hum Antibodies. 2004. PMID: 15598988

6

Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.

Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B, Rolser R, Malikzay A, Persaud A, Corcoran E, Deevi DS, Balderes P, Bassi R, Jimenez X, Joynes CJ, Mangalampalli VR, Steiner P, Tonra JR, Wu Y, Pereira DS, Zhu Z, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Kussie P. Loizos N, et al. Among authors: kussie p. Mol Cancer Ther. 2005 Mar;4(3):369-79. doi: 10.1158/1535-7163.MCT-04-0114. Mol Cancer Ther. 2005. PMID: 15767546

7

Development of heparanase inhibitors for anti-cancer therapy.

Miao HQ, Liu H, Navarro E, Kussie P, Zhu Z. Miao HQ, et al. Among authors: kussie p. Curr Med Chem. 2006;13(18):2101-11. doi: 10.2174/092986706777935230. Curr Med Chem. 2006. PMID: 16918340 Review.

8

Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies.

Lu D, Kussie P, Pytowski B, Persaud K, Bohlen P, Witte L, Zhu Z. Lu D, et al. Among authors: kussie p. J Biol Chem. 2000 May 12;275(19):14321-30. doi: 10.1074/jbc.275.19.14321. J Biol Chem. 2000. PMID: 10799512 Free article.

9

Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.

Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, Kussie P, Koo H, Kim HJ, Lu D, Liu M, Tejada R, Friedrich M, Bohlen P, Witte L, Rafii S. Zhu Z, et al. Among authors: kussie p. Leukemia. 2003 Mar;17(3):604-11. doi: 10.1038/sj.leu.2402831. Leukemia. 2003. PMID: 12646950

10

Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.

Duncton MA, Piatnitski Chekler EL, Katoch-Rouse R, Sherman D, Wong WC, Smith LM 2nd, Kawakami JK, Kiselyov AS, Milligan DL, Balagtas C, Hadari YR, Wang Y, Patel SN, Rolster RL, Tonra JR, Surguladze D, Mitelman S, Kussie P, Bohlen P, Doody JF. Duncton MA, et al. Among authors: kussie p. Bioorg Med Chem. 2009 Jan 15;17(2):731-40. doi: 10.1016/j.bmc.2008.11.049. Epub 2008 Nov 24. Bioorg Med Chem. 2009. PMID: 19101155

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters